January 29, 2024

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

January 11, 2024

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

December 18, 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

December 05, 2023

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

November 13, 2023

Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

October 18, 2023

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

October 02, 2023

Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds

September 21, 2023

Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference

September 06, 2023

Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

August 14, 2023

Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

July 31, 2023

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market

July 27, 2023

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

June 28, 2023

Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing

May 23, 2023

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 15, 2023

Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

March 31, 2023

Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

March 30, 2023

Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

March 02, 2023

Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

February 21, 2023

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 17, 2023

Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference

January 04, 2023

Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

December 15, 2022

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 05, 2022

Checkpoint Therapeutics Announces Reverse Stock Split

November 08, 2022

Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

September 22, 2022

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

September 08, 2022

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

August 12, 2022

Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

June 16, 2022

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

June 06, 2022

Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 19, 2022

Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

May 13, 2022

Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

May 12, 2022

Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

April 28, 2022

Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

April 04, 2022

Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

March 28, 2022

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

January 25, 2022

Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference

January 25, 2022

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

December 08, 2021

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

November 04, 2021

Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results

September 22, 2021

Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

September 09, 2021

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

August 05, 2021

Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results

July 08, 2021

Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

May 12, 2021

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

May 06, 2021

Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

March 09, 2021

Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

March 04, 2021

Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference

March 01, 2021

Checkpoint Therapeutics Announces Formation of Scientific Advisory Board

January 06, 2021

Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences

November 09, 2020

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting